code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half avapro history 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. EU.

dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, avapro history 65%Therapeutic considerationsLicence data EU, USPregnancy avapro history D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is avapro history marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names avapro history Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 avapro history See also[edit] Clinical useMain article: Angiotensin II receptor antagonists, avapro history is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade.

to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are.